Silexion Therapeutics (SLXN) AI Stock Analysis

• Market Cap: $5.54M
• Dividend Yield: N/A
• Average Volume (3M): 50.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.28
• Revenue Growth: N/A
• EPS Growth: 91.47%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.88
• Shares Outstanding: 3,330,785
• 10 Day Avg. Volume: 60,134
• 30 Day Avg. Volume: 50,136
• PEG Ratio: 0.28
• Price to Book (P/B): -47.15
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -22.34
• Enterprise Value/Market Cap: -1.42
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 1.12K
• Enterprise Value/Ebitda: 1.05
• 1Y Price Target: $9.00
• Price Target Upside: 324.53% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -4.4
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $2.00 ▼(-5.66% Downside)
• Action: Reiterated Date: 02/03/26
• Date: Action: Reiterated 02/03/26

The score is held down primarily by weak financial performance (no revenue, ongoing losses, and rising cash burn) and bearish technicals (below major moving averages with negative MACD). Positive corporate events around SIL204 regulatory and trial progress provide meaningful upside optionality but are not enough to outweigh the current funding dependence and downtrend.

Positive Factors

Broad, potent preclinical efficacy of SIL204

Demonstrated >90% inhibition across multiple KRAS mutations and tumor types indicates a platform-level therapeutic effect. This breadth strengthens the company’s competitive position in pan-KRAS RNAi, increasing the odds of multiple clinical opportunities and strategic partnerships over the next 2–6 months and beyond.

Completion of toxicology with no systemic organ toxicity

Clear two‑species toxicology with no systemic organ toxicity materially reduces preclinical safety risk ahead of human dosing. That durable de‑risking supports on-time regulatory filings, trial starts, and more credible partner discussions, improving execution probability for clinical milestones.

Regulatory progress toward Phase 2/3 trial

Submission of a Phase 2/3 application plus positive regulator feedback provides structural clarity on trial design and pathway to pivotal data. Regulatory alignment increases probability of timely trial initiation and eventual data that could enable licensing, partnerships, or larger funding rounds.

Negative Factors

Pre-revenue with rising cash burn

Sustained negative operating and free cash flow (~-$10.7M TTM) without commercial revenue creates persistent funding dependence. Over the medium term this raises dilution and liquidity risks, constraining R&D pacing and partner negotiation leverage unless substantial external capital is secured.

Historically weak balance sheet and limited asset base

Improved reported equity masks prior negative equity and a small asset base (~$11.6M). High debt-to-equity signals mixed leverage metrics. This limited financial cushion reduces resilience to trial delays or cost overruns and increases reliance on timely external financing.

Single‑asset, high clinical execution risk

As a development-stage firm concentrated on SIL204, company value is highly contingent on clinical success and regulatory approvals. A single pivotal program creates binary outcomes: trial failure or delay would materially impair prospects, while success is required to sustain long‑term commercial viability.

Silexion Therapeutics Business Overview & Revenue Model

Company Description

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

How the Company Makes Money

Silexion Therapeutics generates revenue primarily through the sale of its proprietary pharmaceutical products, which are developed in-house and marketed globally. The company also engages in licensing agreements with other pharmaceutical firms, allowing them to commercialize Silexion's patented technologies in exchange for royalties and milestone payments. Additionally, strategic partnerships with research institutions and healthcare providers contribute to its earnings by facilitating collaborative development projects and expanding its market reach.

Silexion Therapeutics Financial Statement Overview

Summary

Pre-revenue business with persistent losses and worsening cash burn (TTM operating cash flow and free cash flow about -$10.7M). Balance sheet has improved to positive equity (~$7.0M TTM) and modest absolute debt (~$0.5M), but overall financial resilience is still weak given no revenue base and ongoing reliance on external funding.

Income Statement

The company has reported zero revenue across all periods provided, while losses have widened significantly versus earlier years. TTM (Trailing-Twelve-Months) net loss is about $7.5M (vs. ~$16.4M in 2024, ~$4.9M in 2023), highlighting a business still in a pre-commercial, cash-burning phase with limited visibility to self-sustaining profitability. The main strength is that the loss level is lower than the 2024 annual loss, but overall profitability remains deeply negative with no revenue base.

Balance Sheet

The balance sheet shows a notable improvement in reported equity: TTM (Trailing-Twelve-Months) stockholders’ equity is positive (~$7.0M) versus negative equity in 2022–2024, which reduces immediate balance-sheet distress. However, leverage signals are mixed: total debt is modest in absolute terms (~$0.5M TTM), but the provided debt-to-equity ratio is very high, and prior years included negative equity (a red flag for financial resilience). Total assets are ~$11.6M TTM, suggesting some asset base, but the history of weak equity and ongoing losses remains a key risk.

Cash Flow

Cash generation is weak and deteriorating: TTM (Trailing-Twelve-Months) operating cash flow is about -$10.7M and free cash flow is about -$10.7M, worse than the -$8.4M free cash flow in 2024 and -$4.5M in 2023. Free cash flow is consistently negative, indicating continued reliance on external funding. A minor positive is that cash outflow broadly tracks accounting losses (free cash flow roughly in line with net loss), but the overall trajectory points to rising cash burn.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-7.00K	0.00	0.00	0.00	0.00	0.00
EBITDA	-7.48M	-16.48M	-4.64M	-3.80M	-755.00K	-195.86K
Net Income	-7.53M	-16.44M	-4.94M	-3.21M	-755.22K	-195.86K
Balance Sheet
Total Assets	11.61M	2.86M	5.26M	9.33M	115.41M	129.40K
Cash, Cash Equivalents and Short-Term Investments	9.24M	1.19M	4.59M	8.26M	38.94K	51.70K
Total Debt	485.00K	4.49M	171.00K	271.00K	0.00	0.00
Total Liabilities	4.64M	6.85M	17.31M	16.41M	508.92K	299.39K
Stockholders Equity	6.98M	-3.99M	-15.48M	-10.66M	114.91M	-169.99K
Cash Flow
Free Cash Flow	-10.74M	-8.42M	-4.54M	-3.38M	-1.41M	-75.00K
Operating Cash Flow	-10.73M	-8.40M	-4.53M	-3.33M	-1.41M	-75.00K
Investing Cash Flow	-7.00K	-22.00K	573.00K	-524.00K	0.00	0.00
Financing Cash Flow	18.05M	5.10M	522.00K	2.75M	116.40M	126.70K

Silexion Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLXN, the sentiment is Negative. The current price of 2.12 is above the 20-day moving average (MA) of 1.63, above the 50-day MA of 1.93, and below the 200-day MA of 6.11, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 44.93 is Neutral, neither overbought nor oversold. The STOCH value of 85.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLXN.

Silexion Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GLTO	56 Neutral	$1.69B	-2.32	-114.81%	―	―	37.42%
AEON	54 Neutral	$27.58M	0.22	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RNAZ	49 Neutral	$9.40M	-0.04	-1763.01%	―	―	96.75%
SLXN	46 Neutral	$5.54M	-0.07	-771.23%	―	―	91.47%
MBIO	45 Neutral	$6.76M	-0.73	-418.83%	―	―	98.58%
LYRA	41 Neutral	$2.20M	-0.05	-404.48%	―	-59.21%	68.97%

Silexion Therapeutics Corporate Events

Silexion Highlights SIL204 RNAi Pancreatic Cancer Program Progress

On February 3, 2026, Silexion Therapeutics used a new corporate presentation in a non-deal investor roadshow to highlight the progress and positioning of its RNAi oncology pipeline, led by SIL204, a first-in-class, isoform-selective pan-KRAS silencer formulated with targeted delivery. The company detailed how its dual-administration strategy for SIL204—combining intratumoral endoscopic delivery to penetrate the dense extracellular matrix of primary pancreatic tumors with systemic subcutaneous dosing to reach metastatic lesions—aims to improve outcomes in locally advanced and metastatic pancreatic cancer, as well as other KRAS-driven malignancies. Silexion underscored the magnitude of unmet need in pancreatic cancer, particularly in locally advanced disease where survival is poor and existing small-molecule RAS inhibitors leave significant efficacy and tolerability gaps, and presented Phase 2 data from its first-generation siRNA product Loder showing higher RECIST response rates, increased rates of tumors becoming resectable, and a median overall-survival gain of about 9.3 months versus standard-of-care chemotherapy alone in KRAS G12D/G12V locally advanced pancreatic cancer. The company framed SIL204 as a more advanced successor that leverages LDL receptor-mediated uptake, enriched in pancreatic and metastatic cancer cells, to preferentially deliver siRNA to tumors and potentially establish one of the most advanced RNAi-based oncology products in a highly competitive, high-mortality cancer market.

The most recent analyst rating on (SLXN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Silexion outlines 2026 plans after transformational 2025 progress

On January 6, 2026, Silexion Therapeutics released a CEO letter to shareholders detailing what it called a transformational 2025, highlighted by strong preclinical data for its lead RNAi asset SIL204, which showed over 90% inhibition of KRAS-mutated cancer cell growth across multiple mutations and tumor types, including pancreatic, colorectal, lung and other solid tumors. During 2025 the company also completed two-species toxicology studies with no systemic organ toxicity observed, received positive guidance from Germany’s BfArM on a planned Phase 2/3 trial design in locally advanced pancreatic cancer, secured manufacturing and clinical development partners, raised more than $18 million in financing and regained full Nasdaq compliance, steps that collectively move SIL204 closer to first-in-human testing and strengthen the firm’s positioning in the emerging pan-KRAS therapy space. Looking ahead, Silexion has completed regulatory submissions in Israel for a Phase 2/3 trial in locally advanced pancreatic cancer and plans additional filings in Germany, other EU countries and the U.S. in 2026, with a trial design that includes a safety run-in in combination with standard chemotherapy followed by a randomized expansion, a program it believes could generate pivotal human data to underpin future partnerships and funding while addressing a major unmet need in KRAS-driven cancers.

The most recent analyst rating on (SLXN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Silexion Therapeutics Submits Phase 2/3 Trial Application

On December 16, 2025, Silexion Therapeutics announced the submission of a Phase 2/3 clinical trial application in Israel for their siRNA therapy, SIL204, targeting locally advanced pancreatic cancer. This regulatory milestone follows successful preclinical studies and positive feedback from German authorities, positioning Silexion to initiate trials in Q2 2026, with further filings planned for Germany and the EU in Q1 2026 and potential U.S. expansion thereafter.

The most recent analyst rating on (SLXN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Silexion Therapeutics Gains Positive Feedback for SIL204 Trial

On December 2, 2025, Silexion Therapeutics announced it received positive feedback from the German Federal Institute for Drugs and Medical Devices (BfArM) regarding the design of its Phase 2/3 clinical trial for SIL204, a treatment for pancreatic cancer. This feedback is a significant milestone, providing regulatory clarity and supporting the company’s trajectory towards initiating the trial in the first half of 2026, pending regulatory approvals in Israel and Germany. The company is actively preparing for the trial launch, including manufacturing readiness and clinical site preparations.

The most recent analyst rating on (SLXN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Silexion Completes Toxicology Studies for SIL204 Therapy

On November 25, 2025, Silexion Therapeutics announced the successful completion of toxicology studies for SIL204, a next-generation RNA silencing therapy targeting mutated KRAS oncogenes, ahead of its planned Phase 2/3 clinical trial in locally advanced pancreatic cancer. The studies confirmed no systemic organ toxicity, allowing the company to proceed with regulatory submissions in Israel and Germany and stay on track to initiate the trial in Q2 2026. This advancement strengthens Silexion’s position in the biotechnology industry, offering a promising treatment modality for aggressive cancers and potentially improving survival rates for patients with pancreatic cancer.

The most recent analyst rating on (SLXN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.